Mark Leonard Singleton net worth and biography

Mark Singleton Biography and Net Worth

CFO of Bioventus

Mark Singleton serves as the Company’s Senior Vice President, Chief Financial Officer and Principle Accounting Officer.

Mr. Singleton has more than two decades of experience in operational finance and mergers & acquisitions at large and multi-national organizations. Mark was also involved in initiating the Vascular Solutions acquisition which became a separate business unit at Teleflex.

Previous to this role, Mr. Singleton served as Vice President of Finance of Teleflex’s Vascular business where he had financial responsibility for the $1.7 billion Americas business. Prior to Teleflex, he spent nearly two decades at Lenovo/IBM, where he held a number of senior leadership positions, including EMEA CFO, Western Europe CFO, North America CFO, and Think Business Group CFO.

Mr. Singleton earned his Master of Business Administration from Duke University’s Fuqua School of Business and completed his Bachelor of Science in Finance from Purdue University.

What is Mark Leonard Singleton's net worth?: The estimated net worth of Mark Leonard Singleton is at least $1.22 million as of April 11th, 2025. Singleton owns 141,088 shares of Bioventus stock worth more than $1,216,179 as of March 13th. This net worth approximation does not reflect any other assets that Singleton may own. Learn More about Mark Leonard Singleton's net worth.
How do I contact Mark Leonard Singleton?: The corporate mailing address for Singleton and other Bioventus executives is 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM, NC, 27703. Bioventus can also be reached via phone at (919) 474-6700 and via email at [email protected]. Learn More on Mark Leonard Singleton's contact information.
Has Mark Leonard Singleton been buying or selling shares of Bioventus?: Mark Leonard Singleton has not been actively trading shares of Bioventus during the last ninety days. Most recently, Mark Leonard Singleton sold 3,875 shares of the business's stock in a transaction on Friday, April 11th. The shares were sold at an average price of $7.57, for a transaction totalling $29,333.75. Following the completion of the sale, the chief financial officer now directly owns 141,088 shares of the company's stock, valued at $1,068,036.16. Learn More on Mark Leonard Singleton's trading history.
Who are Bioventus' active insiders?: Bioventus' insider roster includes John Bartholdson (Director), Katrina Church (SVP), Robert Claypoole (CEO), Anthony D'Adamio (SVP), P III (CEO), Michelle Mcmurry-Heath (Director), Guy Nohra (Director), Kenneth Reali (CEO), Mark Singleton (Sr. VP), and Mark Singleton (CFO). Learn More on Bioventus' active insiders.
Are insiders buying or selling shares of Bioventus?: During the last twelve months, insiders at the sold shares 7 times. They sold a total of 53,031 shares worth more than $427,812.14. The most recent insider tranaction occured on March, 11th when Director Michelle Mcmurry-Heath sold 12,000 shares worth more than $105,480.00. Insiders at Bioventus own 33.0% of the company. Learn More about insider trades at Bioventus.
Information on this page was last updated on 3/11/2026.

Mark Leonard Singleton Insider Trading History at Bioventus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/11/2025	Sell	3,875	$7.57	$29,333.75	141,088
3/24/2025	Sell	5,479	$9.79	$53,639.41	131,963
2/18/2025	Sell	6,498	$10.19	$66,214.62	118,817
12/23/2024	Sell	10,733	$10.53	$113,018.49	105,162
6/21/2024	Sell	9,219	$5.57	$51,349.83	84,895
6/17/2024	Sell	13,753	$5.84	$80,317.52	63,114
4/11/2024	Sell	4,000	$4.75	$19,000.00	34,665
3/22/2024	Sell	5,541	$5.39	$29,865.99	25,665
3/24/2023	Sell	6,044	$1.27	$7,675.88	12,581

Mark Leonard Singleton Buying and Selling Activity at Bioventus

Bioventus Company Overview

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Today's Range

Now: $8.62

$8.56

$8.79

50 Day Range

MA: $8.25

$7.57

$9.10

2 Week Range

Now: $8.62

$5.81

$10.13

Volume

286,351 shs

Average Volume

334,578 shs

Market Capitalization

$716.75 million

P/E Ratio

26.12

Dividend Yield

N/A

Beta

0.78